Navigation Links
Signum Dermalogix Investigational New Drug (IND) Application Cleared by FDA: SIG990 a Potential Treatment for Rosacea
Date:7/9/2013

PRINCETON, N.J., July 8, 2013 /PRNewswire/ -- Signum Dermalogix, Inc. ("Dermalogix") a private biopharmaceutical company focused on developing new and innovative dermatological products and services announced that its Investigational New Drug (IND) Application to evaluate SIG990 in rosacea has been cleared by the U.S. Food and Drug Administration (FDA).

SIG990 is a safe topical treatment that addresses both erythema and inflammatory lesions and thus would be a significant and potentially better therapeutic option for rosacea patients then what is currently on the market. SIG990 is an isoprenylcysteine (IPC) analog that modulates toll-like receptor (TLR) and G-protein signaling demonstrating promising results in several in vitro cell based assays and efficacy in in vivo topical inflammatory animal models.

Instrumental in the pre-clinical development of SIG990 was funding from the National Institute of Allergy and Infectious Diseases (NIAID) via an SBIR grant. Dr. Eduardo Perez, VP of R&D and Business Development stated, "We thank NIAID for their support of this program. We would not have been able to perform the critical safety, pharmacology and manufacturing required without this grant support."

As a new chemical entity, SIG990 recently had composition of matter IP awarded (US Patent Application No. 12/566,839). Maxwell Stock, CEO of Dermalogix, commented, "We continue to make significant progress and are well-positioned to advance the development of our IPC compounds in dermatology. I look forward to moving SIG990 into the clinic to assess its efficacy in human subjects."

About Signum Dermalogix
Signum Dermalogix, is a dermatological focused company, developing novel cosmetic ingredients and drug compounds. Dermalogix also provides dermatology testing, custom assay development and analytical services. For more information please visit: www.signumdermalogix.com


'/>"/>
SOURCE Signum Dermalogix, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Sanofi Pasteur Presents Pediatric Data on Investigational Quadrivalent Influenza Vaccine
2. Data from Study of Elderly Depressed Patients are Reported for Investigational Compound Lu AA21004 on Symptoms of Major Depressive Disorder (MDD)
3. Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor
4. Results of Phase II Study of Boehringer Ingelheims Investigational Bronchodilator for COPD Presented at 2012 ATS International Conference
5. Lilly Diabetes Presents Phase II Blood Pressure and Heart Rate Data on Investigational GLP-1 Analog Candidate, Dulaglutide, in Patients with Type 2 Diabetes at the 27th American Society of Hypertension Scientific Meeting
6. Lilly and Boehringer Ingelheim Present Data at the 72nd American Diabetes Association Scientific Sessions® from Phase II Studies Comparing Investigational Novel Basal Insulin to Insulin Glargine
7. Abbott Presents Results of Clinical Studies Evaluating Its Investigational Treatment for Advanced Parkinsons Disease
8. Results For Phase 2b Trial Of Unique Investigational Cell-Based Therapy In Venous Leg Ulcers Published In The Lancet
9. Janssen Biotech Announces Global License and Development Agreement for Investigational Anti-Cancer Agent Daratumumab
10. Clinical Study With Investigational Cream Aims To Help Women Who Experience Painful Sex
11. Omeros Files Investigational New Drug Application for Lead Compound in PDE10 Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... 2, 2016 Research and Markets has announced ... Growth and Demand Forecast to 2022" report to their offering. ... , , ... in 2015, and it is expected to grow at a CAGR of ... to witness faster growth during the forecast period, a CAGR of 8.8% ...
(Date:12/2/2016)... Dec. 2, 2016 In the first ever ... from those derived from C. sativa, the Hebrew University ... di Napoli Federico II , the Universita` del Piemonte ... comprehensive, critical, integrated and unified inventory of phytocannabinoids of ... focuses on the remarkable chemical and structural diversity of ...
(Date:12/2/2016)... , Dec. 2, 2016  Maxor National Pharmacy Services, ... of Pharmaceutical Specialties, Inc. ("PSI").  The combination of ... Georgia -based PSI bring together both company,s clinical ... manufacturers, and payers an industry-leading specialty pharmacy. About ... , , ...
Breaking Medicine Technology:
(Date:12/5/2016)... , ... December 05, 2016 , ... ... today that they have teamed up with The American College of Surgeons (ACS) ... ACS’s Committee on Trauma, the “Bleeding Control Basic” course is a pilot program ...
(Date:12/4/2016)... ... December 03, 2016 , ... The Lymphoma Research ... lymphoma research and serving the lymphoma community through a comprehensive series of education ... Tasting Event in New York City, with long-time partners The Paul Foundation, on ...
(Date:12/4/2016)... ... December 03, 2016 , ... Houston ... the 2016 Anti-Aging & Beauty Awards at The Aesthetic & Anti-aging Medicine ... Medicine European Congress (AMEC) brings together the industry’s leading scientific experts, speakers, ...
(Date:12/4/2016)... ... December 04, 2016 , ... ... cosmetic surgery can now take advantage of a cosmetic procedure known as ... treatment that reduces the appearance of age spots, fine lines, uneven coloration, ...
(Date:12/2/2016)... ... December 02, 2016 , ... Halfway through its partnership with First 5 ... services to more than 15,900 children 5 years old and younger and treatment services ... over a span of five years to Western University of Health Sciences, UCLA and ...
Breaking Medicine News(10 mins):